Unknown

Dataset Information

0

An epigenetic aging analysis of randomized metformin and weight loss interventions in overweight postmenopausal breast cancer survivors.


ABSTRACT: Metformin and weight loss relationships with epigenetic age measures-biological aging biomarkers-remain understudied. We performed a post-hoc analysis of a randomized controlled trial among overweight/obese breast cancer survivors (N = 192) assigned to metformin, placebo, weight loss with metformin, or weight loss with placebo interventions for 6 months. Epigenetic age was correlated with chronological age (r = 0.20-0.86; P < 0.005). However, no significant epigenetic aging associations were observed by intervention arms. Consistent with published reports in non-cancer patients, 6 months of metformin therapy may be inadequate to observe expected epigenetic age deceleration. Longer duration studies are needed to better characterize these relationships.Trial Registration: Registry Name: ClincialTrials.Gov.Registration Number: NCT01302379.Date of Registration: February 2011.URL: https://clinicaltrials.gov/ct2/show/NCT01302379.

SUBMITTER: Nwanaji-Enwerem JC 

PROVIDER: S-EPMC8684118 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC4443974 | biostudies-literature
| 2114276 | ecrin-mdr-crc
| S-EPMC5323258 | biostudies-literature
| S-EPMC10421485 | biostudies-literature
| S-EPMC7334095 | biostudies-literature
| S-EPMC3660120 | biostudies-literature
| S-EPMC8094215 | biostudies-literature
| S-EPMC4818156 | biostudies-other
| S-EPMC6890496 | biostudies-literature
| S-EPMC4516992 | biostudies-literature